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In Vitro-Selected Drug-Resistant Varicella-Zoster Virus Mutants in the
Thymidine Kinase and DNA Polymerase Genes Yield Novel
Phenotype-Genotype Associations and Highlight Differences between
Antiherpesvirus Drugs
G. Andrei,a D. Topalis,a P. Fiten,b C. McGuigan,c J. Balzarini,a G. Opdenakker,b and R. Snoecka
Laboratory of Virologya and Laboratory of Immunobiology,b Rega Institute for Medical Research, K. U. Leuven, Belgium, and Welsh School of Pharmacy, Cardiff University,
Cardiff, United Kingdomc
Varicella zoster virus (VZV) is usually associated with mild to moderate illness in immunocompetent patients. However, older
age and immune deficiency are the most important risk factors linked with virus reactivation and severe complications. Treat-
ment of VZV infections is based on nucleoside analogues, such as acyclovir (ACV) and its valyl prodrug valacyclovir, penciclovir
(PCV) as its prodrug famciclovir, and bromovinyldeoxyuridine (BVDU; brivudin) in some areas. The use of the pyrophosphate
analogue foscarnet (PFA) is restricted to ACV-resistant (ACVr) VZV infections. Since antiviral drug resistance is an emerging
problem, we attempt to describe the contributions of specific mutations in the viral thymidine kinase (TK) gene identified fol-
lowing selection with ACV, BVDU and its derivative BVaraU (sorivudine), and the bicyclic pyrimidine nucleoside analogues
(BCNAs), a new class of potent and specific anti-VZV agents. The string of 6 Cs at nucleotides 493 to 498 of the VZV TK gene ap-
peared to function as a hot spot for nucleotide insertions or deletions. Novel amino acid substitutions (G24R and T86A) in VZV
TKwere also linked to drug resistance. Six mutations were identified in the “palm domain” of VZVDNA polymerase in viruses
selected for resistance to PFA, PCV, and the 2-phophonylmethoxyethyl (PME) purine derivatives. The investigation of the con-
tributions of specific mutations in VZV TK or DNA polymerase to antiviral drug resistance and their impacts on the structures
of the viral proteins indicated specific patterns of cross-resistance and highlighted important differences, not only between dis-
tinct classes of antivirals, but also between ACV and PCV.
Varicella-zoster virus (VZV), one of the eight human herpesvi-ruses, is classified together with herpes simplex virus types 1
(HSV-1) and 2 (HSV-2) in the subfamily Alphaherpesvirinae. Fol-
lowing primary infection, VZV causes varicella (chickenpox),
characterized by a generalized vesicular rash. Varicella, one of the
most contagious infectious diseases in humans, is mainly a child-
hood disease in unvaccinated populations. Although varicella is
usually a mild to moderate illness in immunocompetent patients,
primary or secondary immunodeficiency is associated with seri-
ous complications, such as central nervous system involvement,
pneumonia, and secondary bacterial infection, that can lead to the
death of the infected patient (22). Older age and possibly preg-
nancy are also important risk factors associated with severe vari-
cella and fatal outcome (59).
Subsequent to primary infection, the virus remains latent in
the dorsal root ganglia of the host, and reactivation may occur
several years or decades later, resulting in herpes zoster (HZ), also
known as shingles. A painful vesicular rash with a dermatomal
distribution characterizes HZ. Postherpetic neuralgia (PHN), the
persistence of pain after resolution of the HZ rash, is the most
troublesome complication associated with HZ. Worldwide, HZ
affects millions of individuals, and a decline in VZV-specific cell-
mediated immunity (CMI) because of aging or immunosuppres-
sion increases the risks of VZV reactivation (54, 55, 64).
A live-attenuated vaccine is available for the prevention of vari-
cella, and its use in the pediatric population since 1995 has re-
sulted in a significant reduction in the incidence of varicella. How-
ever, in rare circumstances in immunosuppressed children who
were undiagnosed at the time of vaccination, the vaccine has
caused severe infections or disseminated disease that required
prompt and prolonged treatmentwith antivirals (10, 17, 30, 35). A
zoster vaccine is also approved by the Food andDrug Administra-
tion (FDA) for prevention of HZ in adults 60 years of age and
older (19). The vaccine has proven to be safe and partially effective
in preventing both HZ and PHN (20, 34, 46).
Varicella is generally a self-limiting disease, and in most cases,
symptomatic treatment is sufficient (59), but specific antiviral
therapy for varicella is required for groups of people at risk for
severe disease (22). Therapy for HZ is warranted to accelerate
healing, diminish the duration of acute and chronic pain, and
reduce the risk of PHN. Additionally, in immunocompromised
patients, antiviral therapy for HZ is needed to limit the risk of
dissemination of VZV (1, 68). Acyclovir (ACV), valacyclovir (an
oral prodrug of ACV), and famciclovir (an oral prodrug of penci-
clovir [PCV]) are approved for the treatment of VZV infections.
Brivudin (BVDU; bromovinyldeoxyuridine) has been licensed for
the therapy ofHZ in some European countries. Both brivudin and
its arabinofuranosyl analogue sorivudine (BVaraU) are contrain-
dicated in patients with cancer because they can bemetabolized to
the free base (E)-5-(2-bromovinyl)uracil, which blocks the degra-
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dation of the anticancer drug 5-fluorouracil (5-FU), resulting in
the accumulation of high (toxic) 5-FU levels (9).
Although ACV resistance (ACVr) is virtually unobserved in
immunocompetent patients, it can be a major problem among
immunosuppressed hosts, mainly those who have received pro-
longed ACV therapy (25, 36, 42, 58). Approximately 30% of VZV
infections clinically resistant to ACV are associated with virologi-
cal resistance (our unpublished data). A lack of clinical response to
ACV has been correlated with the presence of thymidine kinase
(TK)-deficient or TK-altered virus, although a few cases were doc-
umented with an alteration in DNA polymerase (Pol) (18). Thus,
themolecular basis for resistance to ACV is linked tomutations in
either the viral TK or the DNA Pol gene. Herpesvirus TKs are able
to transfer a -phosphoryl group from ATP to the 5= hydroxyl
group of thymidine (13). In addition, VZV and HSV-1 TKs pos-
sess thymidylate kinase activity, which converts dTMP to dTDP.
Then, the conversion to dTTP is carried out by cellular kinases.
Herpesvirus TKs have a broader substrate specificity than mam-
malian cytosolic TKs and can phosphorylate many nucleoside an-
alogues, such as ACV, PCV, GCV, BVDU, BVaraU, and the bicy-
clic pyrimidine nucleoside analogues (BCNAs), a new class of
extremely potent and specific anti-VZV agents (5, 38). The differ-
ence in substrate specificity between cellular and viral TKs is the
basis for the selectivity of nucleoside analogues as antiherpetic
compounds.
Because most ACVr VZV strains have alterations in the viral
TK (31, 33, 41, 47, 49, 53), foscarnet (PFA) (a direct inhibitor of
viral DNA Pol) is the drug of choice to treat ACVr VZV infections
(1, 11, 21, 32, 48). A few reports have describedVZVmutants with
alterations at the level of DNA Pol associated with resistance to
PFA (26, 66, 67). The acyclic nucleoside analogues (ANPs), such
as cidofovir, which do not require activation by the virus-encoded
TK, can be considered alternatives for the treatment of ACVr
and/or PFAr mutants, as shown in the cases of HSV-1 andHSV-2.
In several studies, laboratory and clinical ACVr VZV mutants
were reported (8, 14, 28, 62). However, investigations correlating
a detailed phenotype with specific mutations in the VZV TK and
DNA Pol genes are lacking. The analysis of drug resistance with
VZV is more complex than with HSV because VZV is normally
cell associated, with only a very small fraction of cell-free virus,
making it difficult to isolate pure populations of viruses. In the
present study, we were interested in genotyping previously iso-
lated drug-resistant VZV emerging under selective pressure with
different classes of antiherpesvirus agents, including ACV, PCV,
BVDU, BVaraU, four different BCNAs, the pyrophosphate ana-
logue PFA, and twoANPs (i.e., 2-phophonylmethoxyethyl [PME]
purine derivatives) (2, 3). Furthermore, the contributions of spe-
cificmutations in VZVTKorDNAPol to antiviral drug resistance
and their impacts on the structures of viral proteins were investi-
gated. Our results revealed patterns of cross-resistance associated
with specific mutations in VZV TK and DNA Pol and highlight
important differences, not only between distinct classes of antivi-
rals, but also between members of one defined structural class of
drugs (i.e., ACV and PCV).
MATERIALS AND METHODS
Cells and viruses. Human embryonic lung (HEL) fibroblasts (ATCC
CCL-137) were maintained in minimum essential medium (MEM) sup-
plemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM
L-glutamine, and 0.3% sodium bicarbonate. The VZV laboratory strain
Oka (ATCC VR-795) was used.
Compounds. The sources of the compounds were as follows: acyclovir [9-
(2-hydroxyethoxymethyl)guanine], GlaxoSmithKline, Stevenage, United King-
dom; the pyrophosphate analogues foscarnet (phosphonoformate sodium salt)
and phosphonoacetic acid (PAA), SigmaChemicals, St. Louis,MO; PMEA {ad-
efovir; 9-[2-(phophonylmethoxyethyl)adenine] and (S)-HPMPC [cidofovir;
CDV; (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]}, Gilead
Sciences, Foster City, CA; (S)-HPMPA [(S)-9-(3-hydroxy-2-phosphonyl-
methoxypropyl)adenine], PMEDAP [9-(2-phosphonylmethoxyethyl)-2,6-
diaminopurine],Marcela Krécmerova, Institute of Organic Chemistry and Bio-
chemistry, Academy of Sciences of the Czech Republic, Prague, Czech
Republic; brivudin [(E)-5-(2-bromovinyl)-1(-D-2=-deoxyribofuranos-1-yl-
uracil], Searle, United Kingdom; sorivudine [1--D-arabinofuranosyl-(E)-
5-(2-bromovinyl)uracil], Yamasa Shoyu, Koshi, Japan; ganciclovir [GCV; 9-
(1,3-dihydroxy-2-propoxymethyl)guanine], Roche, Basel, Switzerland;
penciclovir [9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine], Aventis, Frank-
furt, Germany; the BCNAs, i.e., Cf1368 {3-](2R,4S,5R)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl]-6-octylfuro[2,3-d]pyrimidin-2(3H)-
one}, Cf1603 {6-decyl-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)
tetrahydrofuran-2-yl]thieno[2,3-D]pyrimidin-2(3H)-one}, Cf1742 {6-(4-
hexylphenyl)-3-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-
yl]furo[2,3-D]pyrimidin-2(3H)-one}, and Cf1743 {3-[(2R,4S,5R)-4-hydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl]-6-(4-pentylphenyl)furo[2,3-D]
pyrimidin-2(3H)-one}, ChrisMcGuigan,CardiffUniversity,UnitedKingdom.
Selection of drug-resistant virus clones by multiple-step selection.
The drug-resistant virus strains were obtained by serial passage of the
reference Oka strain in the presence of increasing concentrations of the
compounds, as described previously (2, 3). Briefly, the cell-associated
viruswas passaged inHEL cells in the presence of the compounds, starting
at the 50% inhibitory concentrations (IC50s). The cell cultures were incu-
bated until the virus cytopathic effect (CPE) was about 70%, and the drug
concentration was increased 2-fold with every subsequent passage of the
virus. Additional passages of the viruses in the absence of compounds
were often necessary to amplify virus production before a subsequent
passage in the presence of compound. After reaching the highest possible
concentration, a final passage was done in drug-free medium in order to
obtain the virus stock. The drug-resistant strains were titrated, and their
drug susceptibility profiles were determined (2, 3). Subsequently, the dif-
ferent viral strains were plaque purified.
Isolation of plaque-purified viruses. To ensure the presence of a sin-
gle virus population, allmutantswere plaque purified using cell-free virus.
The different drug-resistant strains were plaque purified by limiting dilu-
tion using cell-free virus in HEL cells. The cell-free virus stocks were
prepared by freezing and thawing, followed by sonication in freezing me-
dium consisting of Recovery Cell Culture Freezing Medium (Invitrogen)
supplemented with 5% glycerol and 5% fetal calf serum. Cell-associated
virus stocks of the different plaque-purified clones were prepared and
used to perform antiviral assays and to isolate viral DNA for sequencing of
the viral TK and/or DNA Pol genes.
Antiviral assays. The drug susceptibilities of the different virus clones
were determined by virus plaque reduction assays in HEL cell cultures.
Confluent cultures grown in 96-well microtiter plates were inoculated
with the various virus clones at an input of 20 PFU/well. These assays were
performed as previously described (2). The 50% effective concentration
(EC50) was defined as the drug concentration required to reduce viral
plaque formation by 50%.
Sequencingof theviralORF36 (thymidinekinase) andORF28 (DNA
Pol). VZV drug-resistant plaque-purified strains were cultivated in HEL
cells until 70 to 80% CPE was observed. The infected cells were then
harvested by trypsinization and rinsed once with phosphate-buffered sa-
line. After centrifugation, the cell pellets were immediately used or stored
at 80°C until DNA extraction. DNA was extracted with the QIAamp
blood kit (Qiagen) according to the manufacturer’s instructions. The en-
tire VZV TK gene was amplified from DNA extracted from infected cells
Andrei et al.
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in two overlapping amplicons with the primer sets VZVTKF01 (TCGAC
TAGCGGACATATTTGAAGTTCC) plus VZVTKR02 (TTGCTTACTCT
GGATAAATGACTGG) and VZVTKF02 (AGATACTTAGTGGGAGAT
ATGTCC)plusVZVTKR01 (AACACGTACACGCGAGTATGACAATG)
using the FastStart High Fidelity PCR System (Roche). Four sets of prim-
ers were used to amplify the entire VZV DNA Pol gene: set A, VZVDPF
(TATGTATTAGAAGGGCGTGGGGTTG) and VZVDPR1509 (AGATA
TGAGACCGTTGATC); set B, VZVDPF1353 (TGATTGGGCGTTTATT
ATGGAGAAAC) and VZVDPR2219 (ACACCCAGCAGACTTTCTCGA
ACG); set C, VZVDPF2072 (TTCAGGCCCATAACTTATGTTTTACC)
and VZVDPR2946 (TGCATCTGCAATTATGCGTCCAAACC); and set
D, VZVDP2793 (TAACGATTATGCCCGCAAACTTG) andVZVDPR (T
TACTGTCGGTATGTCGCAACCCAG). The PCR products were puri-
fied using a PCR product purification kit (Roche) and sequenced using a
cycle-sequencing kit (Dyenamic dye terminator kit; Amersham Biosci-
ences), specific primers targeting both strands of the TK gene or the DNA
Pol gene, and a capillary DNA sequencing system (MegaBACE 500; Am-
ershamBiosciences). The data were assembled and compared to the DNA
sequences obtained from the wild-type reference Oka strain using Vec-
torNTI (Informax) software.
ModelingofVZV thymidinekinase andDNAPol.Themodel ofVZV
TK bearing mutations associated with drug resistance was constructed
usingArgusLab (Planaria Software LLC, Seattle,WA), based on the crystal
structure of the VZV TK complexed to BVdUMP and ADP (Protein Data
Bank [PDB] code 1OSN) (7).
A homologymodel of the VZVDNAPol active site was built, using the
SWISS-MODEL Workspace, based on the structural information avail-
able for thermostable B-typeDNAPol from theThermococcus gorgonarius
tridimensional structure (PDB code 1TGO) (23, 57). It shares 22% se-
quence identity with VZV DNA Pol. The resulting complexes were visu-
alized, andfigureswere generatedwith the PyMOLgraphic systemv.99rc6
(Schrödinger, LLC).
RESULTS
Genotypic characterization of plaque-purified viruses selected
under pressure with ACV, BVDU, BVaraU, and BCNAs. We
have previously reported on the phenotypic characterization of
VZVmutants selected under pressure with different classes of an-
tiherpesvirus agents (2, 3). Genotyping was performed following
plaque purification (using cell-free virus) of each type of virus
mutant.
Initially, we genotypically characterized (by sequencing of the
viral TK geneORF36) different clones that were isolated following
selective pressure with ACV, PCV, BVDU, and BVaraU (Table 1).
A stop codon at position 192 of the viral TK was detected in all six
BVDUr clones, leading to a nonfunctional truncated protein. A
frameshift reading was observed because of the insertion of a nu-
cleotide at the nucleotide (nt) 493 to 498 stretch of an homopoly-
mer of five cytosines (C) in six out of seven BVaraUr clones or
because of a thymidine deletion at position 641 in the 7th BVaraUr
clone. All ACVr clones also had a C insertion or a nucleotide de-
letion in the nt 493 to 498 homopolymer region of the viral TK
gene. Four out of 16 ACVr clones contained, in addition to the
frameshift reading, a nucleotide substitution that resulted in the
T86A amino acid change. Interestingly, none of the PCV clones
presented alterations at the level of the TK gene, in agreementwith
their phenotyping, which suggested no alterations at the level of
the gene (2).
Due to the high potency and selectivity of the BCNAs as inhib-
itors of VZV (4, 38) and the recent initiation of clinical trials with
one of the BCNAmembers (37, 38), selection of VZVmutants was
also performed for four different BCNAs (i.e., Cf1368, Cf1603,
Cf1742, and Cf1743) (Table 1). All Cf1603r, Cf1742r, and Cf1743r
clones presented a C insertion within the homopolymeric 493 to
498 C stretch. Two Cf1743r clones had, in addition to the 493 to
498 C insertions, a nucleotide substitution at position 256 that led
to the T86A amino acid change. The Cf1368r clones had either an
insertion of 2 nt at position 412 of the viral TK gene, leading to a
frameshift, or a nucleotide substitution responsible for the G24R
amino acid change (two out of five clones).
Modeling of specific mutations in the VZV TK structure. A
diagram of VZV TK, including the amino acid changes known to
be associated with drug resistance or genetic polymorphisms and
mutations identified in the present study, is shown in Fig. 1. The
ATP-binding site, the nucleoside-binding site, and the regions
that are conserved among Herpesviridae TKs are indicated (Fig. 1
and 2A). Three regions are known to be of particular importance
for the function of TK (15). The first critical region is the
phosphate-binding loop (P loop), residues 22 to 27 in VZV TK,
with a network of hydrogen bonds to the - and -phosphates of
ATP (HSV-1 TK residues 59 to 64). The second conserved region,
containing the DRH/Y/Fmotif, is present as D129R130H131 in VZV
TK (D162R163H164 in HSV TK). Residue Asp162 in HSV-1 TK and
the corresponding Asp-129 in VZV are proposed to bind to the
ADP/ATP-binding site via a magnesium ion. The arginine in this
motif appears to be vital for catalysis. The third region is known as
the flap or “lid” in HSV-1 TK (residues 212 to 226). This lysine/
arginine-rich loop encloses the ATP site and makes contacts with
the phosphates. The lid region has been shown to be flexible in
HSV-1TK to adopt open and closed conformations.However, the
equivalent region in VZV TK (residues 184 to 193) is largely dis-
ordered, consistent with the presence of the product or an open
complex where the release of ADP can be facilitated following
catalysis (7).
Most of the mutations found in this study were due to inser-
tions or deletions of nucleotides in VZV TK. Only two novel sub-
TABLE 1 Genotypic characterization of drug-resistant VZV mutants
obtained in vitro under selective pressure with ACV, BVDU, BVaraU,
and the BCNAs
Resistance selection
under pressure
with:
No. of
clones/total
Changes in viral TK associated with
drug resistance
Nucleotide Amino acid
BVDU 6/6 574-G to T E192-stop
BVaraU 6/7 493–498 C insertion Frameshift
1/7 641-T deletion Frameshift
ACV-A 2/4 493–498 C deletion Frameshift
1/4 256-A to G T86A
493–498 C deletion Frameshift
1/4 493–498 C insertion Frameshift
ACV-B 4/4 493–498 C insertion Frameshift
ACV-C 4/4 493–498 C deletion Frameshift
ACV-E 1/4 493–498 C insertion Frameshift
3/4 256-A to G T86A
493–498 C insertion Frameshift
PCV 4/4 None None
Cf1603 6/6 493–498 C insertion Frameshift
Cf1368 3/5 412 insert TA Frameshift
2/5 70-G to A G24R
Cf1742 8/8 493–498 C insertion Frameshift
Cf1743 17/19 493–498 C insertion Frameshift
2/19 256-A to G T86A
493–498 C insertion Frameshift
Drug-Resistant VZV TK and DNA Polymerase Mutants
March 2012 Volume 86 Number 5 jvi.asm.org 2643
 o
n
 February 25, 2014 by Cardiff Univ
http://jvi.asm.org/
D
ow
nloaded from
 
stitutions were found (i.e., G24R and T86A). Twomodels of VZV
TK bearing the mutation G24R (Fig. 2B) or T86A (Fig. 2C) were
generated. Gly-24 is located in the P loop ofVZVTK,which allows
correct positioning of the -phosphate (Fig. 3A). The mutation
G24Rmodifies this conserved sequence of the P loop and its struc-
ture, and this change is expected to prevent the binding of ATP
(ADP in Fig. 3B). Furthermore, the local structure may also be
disturbed by electrostatic repulsion with the side chain of Arg-183
from the lid domain (Fig. 3C). The steric hindrance due to the
arginine side chain disturbs the basemoiety binding. Thus, hydro-
lysis of the -phosphate of the ATP may not be possible, and the
protein loses its kinase catalytic activity. Boivin et al. reported a
G24E amino acid change in VZV TK that was associated with a
TK-deficient phenotype (8). Moreover, Gly-24 in VZV TK is ho-
mologous to Gly-61 in HSV-1 TK, and changes at this position in
HSV-1 have also been associated with acyclovir resistance (44).
Thr-86 is located in the 2 helix, which is important for the
dimerization of VZV TK. Thr-86 can establish interactions with
residues Gln-69 and Asp-148 from the 1 and 5 helices, respec-
tively, andmaintains the cohesion of the three helices (1,2, and
5) that contribute to the interface of dimerization. Themutation
T86A probably destabilizes the tridimensional structure of the
monomer by loss of interactions with Gln-69 and Asp-148, lead-
ing to a mutant virus lacking TK activity. Gaudreau and collabo-
rators showed in previous studies that the Q104H mutation in
HSV-1 TK (homologous to the residue Gln-69 in VZV TK) pro-
duced a catalytically deficient TK enzyme (16). Morfin et al. also
described the mutation Q104-stop (40).
Phenotypic characterizationofplaque-purifiedvirusesbear-
ingmutations in the viral TK gene.The drug susceptibility/resis-
tance profile of plaque-purified viruses isolated following pressure
with the BCNAs was investigated in comparison with mutants
selected under pressure with BVDU and BVaraU. Figure 4 dis-
plays the phenotypic results of representative clones bearing dif-
ferent types of mutations in the TK gene.
Themutants that had frameshift mutations alone or in combi-
nation with the amino acid substitution T86A, the E192-stopmu-
tation, or the G24R amino acid substitution exhibited high levels
of resistance to the TK-dependent drugs BVDU, BVaraU, and the
BCNAs (2-log-fold resistance) (Fig. 4). In addition, the acyclic
nucleoside analogues ACV, PCV, and GCV proved significantly
less active against these mutant viruses, although the increase in
EC50s was only 1.5 to 1.8 log units for ACV and PCV and 0.7 to 1.0
log unit for GCV. As expected, the TKmutants remained sensitive
to the pyrophosphate analogues PFA and PAA and to the ANPs,
including PME and 3-hydroxy-2-phosphonylmethoxypropyl
(HPMP) derivatives.
Genotypic characterization of plaque-purified viruses se-
lected under pressure with PCV, PMEA, PMEDAP, and PFA.
Since the PCVr virus had no mutations at the level of the TK
(Table 1) and presented a phenotype similar to that observed for
mutant viruses isolated under pressure with two PME derivatives
(i.e., PMEA andPMEDAP) and the pyrophosphate analogue PFA,
the DNA Pol genes (ORF28) of these mutant viruses were ana-
lyzed (Fig. 5A). The amino acid substitutionV666L appeared to be
associated with the resistant phenotype seen for the PCVr virus
(Table 2). The plaque-purified viruses selected under pressure
with PMEA presented two amino acid substitutions, i.e., E762D
and L767S (Table 2). The E762D change can be linked to genetic
polymorphism, since an aspartic acid at this position also occurs
in the reference VZV strain Dumas. Thus, the L767S change ap-
peared to be responsible for the resistance phenotype of the
PMEAr viruses. The mutant viruses isolated under pressure with
PFA, PMEA, and PMEDAP also contained the E762D substitu-
FIG 1 Diagram of VZV TK. Mutations that confer drug resistance located in the ATP-binding site, the nucleoside-binding site, and Leu332 are shown in dark
shaded boxes. Mutations found in other conserved regions of the viral TK are shown in lightly shaded boxes, while mutations located in nonconserved regions
of the viral enzyme are shown in open boxes. Mutations found in the present study are underlined.
Andrei et al.
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tion. In addition to this amino acid change, all PMEDAPr clones
had the D668Y substitution. Four out of eight clones also con-
tained the M808V substitution, in addition to the D668Y change
(Table 2).
Two independent selection procedures (A and B) were per-
formed with PFA (Table 2). In all eight clones, the K662E amino
acid change was associated with resistance to PFA. One of the
clones showed an additional M874I substitution.
Modeling of specific mutations in the VZV DNA Pol struc-
ture. DNA Pols are highly conserved among herpesviruses, and
different regions can be distinguished. In VZV DNA Pol, region
III (amino acids 769 to 809) plays an important role in nucleotide
binding, while region II (amino acids 659 to 701) has a function as
the acceptor for hydrolysis of the pyrophosphate (26). In the pres-
ent study, six mutations were identified in the “palm domain” of
the catalytic subunit of VZVDNAPol: K662E, V666L, andD668Y
(subdomain II); L767S (between subdomains VI and III); M808V
(subdomain III); and M874I (between subdomains I and VII)
(Fig. 5A and 6A). Val-666 is highly conserved at homologous po-
sitions among herpesvirus DNA Pols, while Lys-662 and Asp-668
are partially conserved (Fig. 5B). Val-666 and Lys-662 are in direct
interaction with the DNAmolecule and may affect the binding of
the template strand to the active site (Fig. 6A). Themodification of
a positive charge to a negative one, such as in the K662E substitu-
tion, significantly changes the electrostatic environment, causing
electrostatic repulsion with the negative charges of the phosphate
moiety of the DNA molecule. On the other hand, the V666L
change increases steric hindrance, probably affecting the binding
of the DNA molecule. The modification of the template strand
binding, in both cases, may also affect the positioning of the “in-
coming” deoxynucleoside triphosphate (dNTP) to have correct
base pairing.
Asp-668 is located in the active site ofDNAPol, in proximity to
the DNAmolecule. Amutation of Asp to Tyr confers resistance to
PFA, PMEA, and PMEDAP and, in combination with the M808V
change, the drug resistance is extended to ACV. These two amino
acid alterations in DNA Pol may cause fewer modifications in the
local environment than the othermutations, as shown by the drug
resistance profile. Aspartate and tyrosine are polar amino acids
and bear a negative charge despite the aromatic side chain of the
tyrosine. The change of Met-808 to Val-808 is anticipated to de-
crease the steric hindrance of the side chain. The residue Met-808
is located in the conserved region III of the viral DNA Pol, where
different mutations associated with resistance to PFA and ACV
have been described (Fig. 5).
The highly conserved leucine at position 767 establishes hydro-
phobic interactions with Ile-756, stabilizing the two -helices
(which bear the residues Arg-749, Arg-753, and Lys-775) involved
in binding of the “incoming” nucleoside triphosphate. The re-
placement of a leucine with a serine at position 767 introduces a
polar side chain in a nonpolar environment that may disturb the
stability of the secondary structure and the orientation of the he-
lices. This mutation confers resistance to the acyclic nucleo-
sides (ACV and PCV) and nucleotide analogues (PMEA and
PMEDAP), as well as the pyrophosphate analogues (PFA and
PAA).
M874I has been found in combination with the K662E muta-
tion (Fig. 6B). The amino acid change at position 874 may locally
disturb the secondary structure and prevent DNA Pol inhibition
by foscarnet. M874 establishes hydrophobic interactions with Ile-
816 that is not as bulky as the methionine. Consequently, the
interactions might be weaker, and this might destabilize the local
structure, preventing the binding of foscarnet, but also of ACV,
PCV, PMEA, and PMEDAP. The mutational combination of
K662E and M874I confers cross-resistance to nucleoside (ACV
and PCV) and nucleotide (PMEA and PMEDAP) analogues and
foscarnet, just as the single point mutation V666L did.
Phenotypic characterizationofplaque-purifiedvirusesbear-
ingmutations in the viralDNAPol gene.Thedrug susceptibility/
resistance profiles of plaque-purified viruses isolated following
pressure with PCV, PFA, and the PME derivatives are shown in
FIG 2 Models of VZV thymidine kinase bearing point mutations that induce
resistance to nucleoside analogues. (A) Dimer of VZV-TK complexed to ADP
and BVdUMP (blue). The positions of the mutations are shown in green. (B)
Enlarged view of the P loop (cyan) with the G24Rmutation (green). BVdUMP
(blue) is present in the active site of VZV TK. (C) Wild-type VZV TK super-
imposed on the protein bearing the G24R mutation. Thr-86 (red) and the
T86A mutation (green) are surrounded by four helices at the edge of the
dimerization interface. Residues Gln-69 and Asp-148 in interaction with
Thr-86within themonomer are represented in yellow. The hydroxylmoiety of
the T86 side chain is involved in the interaction with Q69 and D148, whereas
the T86A amino acid change prevents these interactions.
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Fig. 7. The clones selected under pressure with PCV bearing the
V666L substitution showed cross-resistance to ACV and the PME
class of ANPs. In addition, this mutation appeared to confer resis-
tance to the pyrophosphate analogues (0.6- to 0.8-log increases in
the EC50s) (Fig. 7) but weakly affected sensitivity to GCV and the
HPMP derivatives (0.6-log increase in the EC50s).
The mutant viruses isolated under PFA pressure contained the
K662Emutation, and one out of eight clones had a second substi-
tution (i.e.,M874I) (Fig. 7). TheK662Emutation conferred a 1- to
1.3-log degree of resistance to the pyrophosphate analogues, while
the levels of resistance to the PMEderivatives, ACVandPCV,were
in the range of 0.65 to 1.0 log unit. The extents of resistance asso-
ciated with the K662E mutation for GCV and the HPMP deriva-
tives were lower (in the range of 0.3 to 0.5 log unit) than with the
V666L mutation.
Clones bearing the L767Smutation showed pronounced levels
of resistance to the PMEderivatives (1.1 to 1.5 log units for PMEA,
PMEDAP, ACV, and PCV). The L767Smutation conferred 0.5- to
0.7-log-unit resistance to the pyrophosphate analogues. An in-
crease in the EC50s of 0.7 to 0.9 log unit was recorded for GCV and
the HPMP derivatives in the clones bearing the L767S mutation.
Clones selected under pressure with PMEDAP contained two
resistance-related mutations (i.e., D668Y and M808V). The
D668Y mutation alone conferred lower levels of resistance to the
PME derivatives and ACV (0.4 to 0.9 log unit) than to the double
mutants (D668Y and M808V) (1.0 to 1.6 log units). While the
D668Y mutation alone did not affect sensitivity to PFA, this mu-
tation, in combination with the M808Vmutation, afforded a 0.5-
log-fold level of resistance to PFA. Neither the D668Y mutation
alone nor in combination with the M808V mutation had an im-
pact on susceptibility to GCV, while they affected sensitivity to the
HPMP derivatives and PCV by approximately 0.5 log unit.
Sensitivity to BVDU and BVaraUwas not significantly affected
by any of the mutations in viral DNA Pol. The mutant viruses
showed a relatively small increase in EC50s for the BCNAs (0.4 to
0.8 log unit) compared to the mutants selected under pressure
with the BCNA-bearing mutations at the level of the TK gene.
DISCUSSION
In the first part of this study, we correlated specific mutations in
VZV TK with detailed phenotyping and analyzed the impacts of
amino acid substitutions associated with drug resistance on the
structure of the viral enzyme. We showed here that the genetic
basis for resistance to the BCNAs, as well as to ACV, BVDU, and
BVaraU, was alterations in the viral TK gene. Mutants arising
under selective pressure with four different BCNAs were investi-
gated, including Cf1743, whose 5= valyl ester (i.e., FV-100) has
been evaluated recently in a clinical phase 2 trial (4, 38, 43). The
data show a therapeutic benefit of FV-100 given at 200 or 400
mg/day in reducing the severity and duration of shingles-related
pain, the incidence of postherpetic neuralgia, and the time to le-
sion healing. A phase 2b trial is envisioned to further explore its
antiviral efficacy. In cell culture, BCNAs display highly potent
anti-VZV activity and have an absolute requirement for VZV TK-
mediated activation for antiviral activity. They were shown to be
efficiently phosphorylated byVZVTK, but not by the TKs of other
herpesviruses, such as HSV-1 and HSV-2 (6). Obligate intracellu-
lar 5= monophosphorylation of Cf1743 is required for biological
activity (37).
Among 67 plaque-purified clones analyzed for alterations at
the level of VZV TK (emerging under ACV, BVDU, BVaraU, and
the four different BCNAs), 55 showed an insertion or a deletion of
aC in a string of 6Cs at nucleotides 493 to 498 of the viral TK gene.
An insertion or a deletion in this run of Cswas found in 8 out of 10
independent selection procedures. Hence, this homopolymer re-
gion appears to function as a hot spot within the VZV TK gene,
producing nonfunctional, truncated TK proteins. This run of 6 Cs
at nucleotides 493 to 498 in the VZV TK gene is not found at
homologous positions in the HSV-1 or HSV-2 TK gene. Two
other frameshift mutations in VZVTKwere due to an insertion of
FIG 3 Enlarged view of the ATP-binding site of VZV TKwith Gly-24 (green; wild-type) (A) or Arg-24 (red; mutant) (B). In the wild-type TK, the ATPmolecule
(ADP in themodel) can interact with the P loop, whereas in the G24Amutant, the side chain of the argininemay prevent the binding because of steric hindrance.
As a result, the binary complex ATP-VZV TK cannot be formed, and the virus lacks TK activity. (C) Furthermore, Arg-183 might be involved in electrostatic
repulsion with Arg-24, disorganizing the local secondary structure. On the right is the TK structure used for modeling studies showing the active site containing
a molecule of ADP (one of the products of the enzymatic reaction, while ATP is the substrate (i.e., the phosphate donor).
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2 nucleotides at position 412 or to a T deletion at nucleotide 641.
These changes did not occur in homopolymeric repeats of VZV
TK. It is intriguing to observe that the major predominant resis-
tance mechanism against VZV TK for the VZV TK-specific
BCNAs is the 493 to 498 C insertion that is also observed for
BVaraU and ACV. Given the high selectivity of BCNAs for VZV
TK, but not HSVTK, onemight have expected unique amino acid
mutations that do not occur with other antiherpesvirus drugs in
VZV TK or in the HSV-1 TK.
In contrast to VZV, sequencing of the TK genes ofHSV from in
vitro-isolated and clinical ACV-resistant mutants revealed the
presence of several homopolymeric nucleotide (G or C) stretches
that function as hot spots (16, 27, 40, 51, 52, 56). Approximately
50% of the cases of ACV resistance in HSV are due to nucleotide
insertions or deletions in homopolymers of Gs or Cs in the viral
TK gene, mainly in the two longest homopolymers, one of 7 Gs
and one of 6 Cs. It appears that the TK genes of high-GC-content
herpesviruses, such as HSV (GC content, 68%) and bovine her-
FIG 4 Resistance properties of plaque-purified drug-resistant VZVmutants (Oka strain) bearingmutations in the viral TK. HEL cells were grown to confluence
in 96-wellmicroplates, infectedwith 20 PFUof each cloned virus, and incubated for 5 dayswith serial dilutions of each test compound. At least three independent
experiments were performed for each test compound. The data are presented as the EC50 for the drug-resistant clones versus the EC50 for the parent VZV clones.
Horizontal lines for each drug and mutant combination indicate the mean values standard deviations.
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pesvirus type 1 (BHV-1) (GC content, 72%), contain several
stretches of Gs or Cs where insertions or deletions of nucleotides
lead to frameshift mutations (39, 51). VZV, which has a markedly
lower GC content (46%) than HSV or BHV, has only a few ho-
mopolymer stretches (three of 5 As, one of 5 Ts, and one of 6 Cs).
According to our results, the stretch of 6 Cs at nucleotides 493 to 498
emerged as the most important hot spot in the VZV TK gene for
insertions or deletions. Hot spots for mutations in canine herpesvi-
rus, another herpesvirus with a lowGC content (32%), has also been
shown tooccur in only two stretches of 8As in the viral TKgene (69).
FIG5 DiagramofVZVDNAPol. (A)Locationsof functional sitesonVZVDNAPoland linearNterminus toCterminusconfigurationof thepolypeptide (not to scale).
The solid boxes show regions numbered I to VII based on conservation among DNA Pols and region A, a region showing slight conservation. The locations of point
mutations that result in altereddrug sensitivity are shownbelow.Novelmutations associatedwithdrug resistancediscovered in thepresent study are at thebottomof the
diagram. (B) Sequence alignment of the conserved regions II and III of HSV-1, HSV-2, human cytomegalovirus (HCMV), and VZVDNA Pols.
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In a recent study, the proportions of short sequence repeats
(SSRs), which include minisatellites, microsatellites, and ho-
mopolymers, were compared among different herpesviruses and
mimivirus (61). Although larger SSRs aremore obvious to the eye,
homopolymers are the most abundant class of SSRs in all viral
genomes analyzed thus far. SSRs are likely to be a common prop-
erty of large DNA viruses, and the authors suggest that homopo-
lymers across the viral genome are mutational hot spots for evo-
lutionary diversity in herpesviruses. VZV andHSV homopolymer
regions are likely sites ofmutation, bothwithin the TK gene and in
the other genes. This study also points to a higher average protein-
coding variation for HSV-1 than for VZV: 1.3% versus 0.2%, re-
spectively. The higher variation in HSV-1 correlated with a higher
G/C percentage overall (68% for HSV-1 versus 46% for VZV) and
in SSRs (84% for HSV-1 and 47% for VZV). Furthermore, a com-
parison of interstrain variation in homologous proteins ofHSV-1,
VZV, and pseudorabies virus (PRV) across 3 HSV-1, 3 PRV, and
18 VZV strains highlighted several proteins that appear to vary
more substantially in one virus than another. Interestingly, UL23
(HSV-1 thymidine kinase) showed a higher percentage of amino
acid variation (1.33%) than the homologs in VZV (ORF36) and
PRV (UL23)with, respectively, 0.39% and 0.31% amino acid vari-
ation across strains.
Another remarkable difference between theHSV andVZVTKs
is the smaller number of genetic polymorphisms in VZV TK than
in HSV-1 and HSV-2 TKs (44). It appears that VZV TK is rela-
tively conserved, and only a very low number of genetic polymor-
phisms have been described (i.e., L288S and S179N). In our study,
the T86A amino acid change in VZV TK always occurred in com-
bination with a deletion or an insertion of a C in the homopoly-
meric stretch of 6 Cs (nt 493 to 498). Considering the high degree
of conservation of VZV TK, the location of Thr-86 in a region
where mutations have been associated with drug resistance, and
its effect on the structure of the viral protein, it can be assumed
that the T86A change may affect the activity of the enzyme. Two
other novelmutations were found inVZVTK that could be linked
to drug resistance: E192-stop (selected under pressure with
BVDU) and the G24R substitution in the ATP-binding site (upon
selection with one of the BCNAs). The importance of the changes
at position G24 in VZV TK is highlighted by its impact on the
structure of the viral enzyme. Furthermore, in a previous work,
Boivin et al. characterized the G24Emutation in the ATP-binding
site of VZV TK, and the phenotype of the clinical strain bearing
this mutation was shown to be TK deficient (8). Mutations at
homologous residues in HSV-1 and HSV-2 (i.e., G61) have also
been linked to drug resistance (44).
Although ACV resistance in HSV and VZVmay involve differ-
TABLE 2 Genotypic characterization of drug-resistant VZV mutants obtained in vitro under selective pressure with PMEA, PMEDAP,
PFA, and PCV
Resistance selection under
pressure with:
No. of
clones/total
Changes in viral DNA Pol associated
with drug resistance
Changes in viral DNA Pol associated
with genetic polymorphisms
Nucleotide Amino acid Nucleotide Amino acid
PMEA 4/4 T2300C L767S G2286T E762D
PMEDAP 4/8 G2002T D668Y G2286T E762D
4/8 G2002T D668Y G2286T E762D
A2422G M808V
PFA/A 6/6 A1984G K662E G2286T E762D
PFA/B 1/2 A1984G K662E G2286T E762D
1/2 A1984G K662E G2286T E762D
G2622A M874I
PCV 4/4 G1996C V666L
FIG6 (A)structuralmodelofVZVDNAPolbasedonthethermostableB-typeDNA
Pol from T. gorgonarius tridimensional structure (PDB code 1TGO). It shares 22%
sequence identitywithVZVDNAPol.The residues that undergo aminoacid changes
inthemutantvirusesarerepresentedinred.Allthemutatedpositionsarepresentinthe
palmdomain(blue)ofVZVDNAPol (grey). (B)MutationsK662EandV666L(blue)
are located in the regionof the palmdomain in direct interactionwith theDNAmol-
ecule.Theresiduesthatbindthe“incoming”dNTParerepresentedinpurpleandcyan.
In this case, a foscarnetmolecule is present in the active site, competingwith thepyro-
phosphate of the dNTP.
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ent mechanisms (i.e., reduction or loss of viral TK activity, alter-
ation of substrate specificity for viral TK, and mutations affecting
DNA Pol), most of the ACVr HSV and VZV strains are TK defi-
cient (18). Our studies are in agreement with these findings (Table
1). Such frameshift mutations, as also observed to occur in the
VZVTK gene under BCNAdrug pressure, resulted in poor, if any,
phosphorylating activity of the mutant TK enzyme, as examined
in the extracts of HEL cell cultures infected with mutant VZV
strains that were selected in the presence of Cf1603 or Cf1743
(data not shown). In contrast, the PCVr viruses had a mutation at
the level of the DNAPol gene. Furthermore, Ida and collaborators
found that the emergence frequency of resistant VZVmutants was
significantly higher following ACV exposure than following PCV
treatment (24). No data are available regarding the isolation of
PCV-resistant mutants in the clinic. This can be explained by the
longer time of exposure to PCV required for selection of resistance
compared to ACV and by the type of mutants isolated, since TK is
not vital for the virus while only a limited number of mutations
that are nonlethal for the virus can occur in viral DNA Pol.
The differences between HSV and VZV regarding selection of
ACVr and PCVr mutants can be explained either by the different
natures of the viruses or by subtle structural differences betweenPCV
and ACV. First, there is a higher number of homopolymer stretches
in HSV TK than in VZV TK, and no long homopolymers of Gs are
found inVZVTK.VZVTKcontains only one runof 6Cs that is a hot
spot for insertion or deletion of G. Second, the triphosphate form of
ACV (ACV-TP) acts as an obligate DNA chain terminator when in-
corporated into thegrowingDNAstrain,while the triphosphate form
of PCV (PCV-TP) can be incorporated into the growingDNAchain,
resulting in limited chain elongation (65). Third, the affinities and
therefore themolecular interactions ofACV, PCV, and their triphos-
phates with the viral TK andDNAPol differ. In herpesvirus-infected
cells, the efficiencyofphosphorylation to the triphosphatederivatives
is higher for PCV than for ACV. Instead, ACV-TP is a more potent
inhibitor of HSV-1 and VZV DNA polymerases than PCV-TP (12).
Fourth, the triphosphate forms ofACVandPCVdiffer in their intra-
cellular half-lives in infected cells (much longer for PCV-
triphosphate than forACV-triphosphate). Fifth, it hasbeenproposed
that ACV-TP may be capable of modifying the enzymatic or proof-
reading properties of HSV DNA Pol to selectively slip or stutter in
regions containing G-C homopolymers and induce frameshift mu-
tations (50, 51). Although theKi of PCV-TP with DNA Pol is signif-
icantly higher than that of ACV-TP, PCV-TP is actually a more effi-
cient and complete DNA chain terminator under physiological
conditions (with competing natural nucleotides present) than is
ACV-TP (12, 45). In conclusion, themore complete DNA chain ter-
mination activity of PCV-TP, the weaker interaction with DNA Pol
than ACV-TP, and the lack of homopolymeric stretches of Gs in the
FIG 7 Resistance properties of plaque-purified drug-resistant VZV mutants (Oka strain) bearing mutations in the viral DNA Pol. HEL cells were grown to
confluence in 96-well microplates, infected with 20 PFU of each cloned virus, and incubated for 5 days with serial dilutions of each test compound. At least three
independent experiments were performed for each test compound. The data are presented as the EC50s for the drug-resistant clones versus the EC50s for the
parent VZV clones.
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VZVTKandPol genesmay explain thedifferences observedbetween
ACV and PCV in the present study. It is worth mentioning that dif-
ferent mutational patterns in TK genes of HSV were reported with
viruses selected in cell culture for resistance to ACV or PCV (50, 60).
Additionally, PCV, similar toGCV,maybephosphorylated, not only
by VZV TK, but also by the protein kinase ORF47, which is homol-
ogous to the HCMV protein kinase UL97.
VZV encodes a protein kinase (ORF47) that is homologous to
theHCMVprotein kinaseUL97. AsHCMVdoes not encode a TK,
the UL97 protein kinase is responsible for GCV activation in in-
fected cells. Koyano et al. (29) analyzed the phosphorylation path-
ways of antiherpesvirus nucleoside analogues by VZV-specific en-
zymes. Cells expressing VZV TK proved to be susceptible to ACV
and GCV, as well as oxetanocin analogues. In contrast, VZV PK-
expressing cells were susceptible only to GCV and oxetanocin an-
alogues, indicating that VZV PK phosphorylates certain nucleo-
side analogues, for example, GCV and oxetanocin. Further
evidence for the activation of GCV and oxetanocin analogues was
provided by the fact that these compounds were able to inhibit the
replication of TK-negative VZV strains at concentrations 10 times
higher than those at which they inhibited wild-type VZV. These
results are in agreement with our phenotyping data for mutant
VZVs bearing different types of changes in the viral TK gene,
which showed an increase in EC50s of only 0.7 to 1.0 log unit
compared to 1.5 to 1.8 log units for ACV and PCV and 2 log
units for BVDU and the BCNAs (Fig. 4).
In the present study, we also investigated the DNA Pol changes
in drug-resistant virus mutants. Since the PCVr plaque-purified
isolates did not show alterations at the level of the TK gene and
showed cross-resistance to the pyrophosphate analogues and the
PME derivatives, we performed genetic analysis of the DNA Pol
gene. PCV seemed to select for virus strains that contain muta-
tions in VZV DNA Pol (i.e., V666L) that were also reported to
occur under PFA pressure (66, 67). Among the four novel muta-
tions (i.e., D668Y, L767S, M808V, and M874I) in the viral DNA
Pol that could be linked to drug resistance, two positions (i.e.,
Met-808 and Leu-767) are conserved among HSV, VZV, and
HCMV, while two are partially conserved (i.e., Asp-668 andMet-
874). Their effects on the structure of VZVDNAPol (Fig. 6 and 7)
highlight the impact of mutations at these positions.
A recent study has highlighted the limitations of employing the
crystal structures of related polymerases, such as that of the bacterio-
phage RB69 or Thermococcus gorgonariusas, as model systems to ex-
plainmechanismsof inhibitionofDNAsynthesis anddrug resistance
(63). It was demonstrated that the RB69 DNA polymerase (gp43) is
400-fold less sensitive to the pyrophosphate analoguePFA than the
HCMVDNApolymerase (UL54). These data point to profound dif-
ferences in sensitivity and selectivity to antiviral drugs when the viral
enzyme is compared with gp43. Critical regions of the nucleotide-
binding site of gp43 were replaced by equivalent regions of the
HCMV enzyme. Interestingly, the chimeric gp43-UL54 enzymes
containing residues of the helix N and helix P of UL54 were resensi-
tized to PFA andACV.Hence, chimeric enzymes can provide a valu-
able tool to study themechanismsof actionandresistance toPFAand
to nucleotide analogue inhibitors.
It should be noted that mutations in viral TK are usually asso-
ciated with high levels of resistance (1 log10-fold increase in
EC50s). In contrast, mutations in viral DNA Pol result in smaller
differences in EC50s between the wild-type and mutant viruses.
Our results illustrate the complexity of themechanisms of her-
pesvirus resistance to antiviral drugs. Although there is conserva-
tion among viral TKs and DNA Pols, marked differences between
VZV and HSV could be found. In addition, differences between
HSV andVZV regarding the types ofmutants selected under ACV
and PCV pressure were observed. The relevance of these findings
to the in vivo situation warrants further investigation.
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